The RPL26L1 antibody is a tool used to detect ribosomal protein L26-like 1 (RPL26L1), a paralog of the ribosomal protein RPL26. Both proteins share structural homology but exhibit distinct expression patterns. RPL26L1 is expressed in specific tissues, including the liver, testis, and certain cancer cells, whereas RPL26 is ubiquitously expressed. RPL26L1 is implicated in ribosome biogenesis and translation regulation, though its precise functional divergence from RPL26 remains under investigation. Studies suggest it may play roles in cell proliferation, differentiation, and stress responses. Dysregulation of RPL26L1 has been linked to cancers (e.g., hepatocellular carcinoma, leukemia) and developmental disorders, making it a potential biomarker or therapeutic target. The antibody, often produced in rabbits or mice, is validated for applications like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions. Its specificity is confirmed using knockout controls or peptide-blocking assays. Commercial RPL26L1 antibodies are available, but validation is crucial due to cross-reactivity risks with RPL26. Research using this antibody has advanced understanding of ribosome heterogeneity and tissue-specific translational regulation, highlighting its importance in molecular and cancer biology.